AM-Pharma adds $131M in series E for SA-AKI study July 16, 2019 By Nuala Moran No Comments LONDON – AM-Pharma BV has raised €116 million (US$130.7 million) in a series E round to fund phase III development of its recombinant alkaline phosphatase, Recap, in the treatment of sepsis-associated acute kidney injury (SA-AKI).Read More